CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.
about
CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
CRISPR/Cas9 editing of Nf1 gen ...... is reversed by (S)-Lacosamide.
@en
CRISPR/Cas9 editing of Nf1 gen ...... lated pain that is reversed by
@nl
type
label
CRISPR/Cas9 editing of Nf1 gen ...... is reversed by (S)-Lacosamide.
@en
CRISPR/Cas9 editing of Nf1 gen ...... lated pain that is reversed by
@nl
prefLabel
CRISPR/Cas9 editing of Nf1 gen ...... is reversed by (S)-Lacosamide.
@en
CRISPR/Cas9 editing of Nf1 gen ...... lated pain that is reversed by
@nl
P2093
P1433
P1476
CRISPR/Cas9 editing of Nf1 gen ...... is reversed by (S)-Lacosamide.
@en
P2093
Chaoling Qu
Frank Porreca
Jennifer Y Xie
Kerry B Gilbraith
Ki Duk Park
Liberty François-Moutal
Lindsey A Chew
May Khanna
Mohab M Ibrahim
Rajesh Khanna
P304
P356
10.1097/J.PAIN.0000000000001002
P407
P50
P577
2017-12-01T00:00:00Z